Trial
NCT05307679
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Dup15q Syndrome
Intervention
Basmisanil
Why stopped
The study was terminated due to sponsor decision and not related to safety or tolerability.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-12